[ad_1]
An investment for Solgate: the Lower Austrian startup concludes a seed funding round with the IST cube Venture Fund and private investors. Founded in 2020 by Ariel Bensimon, Georg Winter, Stefan Kubicek, Giulio Superti-Furga, and Gaia Novarino together with IST Austria and CeMM, Solgate is investigating the development of new drugs.
Solgate: Research on New Drugs
According to its own statement, the startup uses “methods of modern chemistry, cell biology and analytics.” The new drugs will be developed on the basis of an “important class of proteins, but so far largely unused.” These are known as “solute carriers”. Ariel Bensimon, co-founder and CEO of Solgate, explains the advantage of these special proteins: “Solute carriers are extremely interesting therapeutic targets. They have the potential to enable real advances in the therapy of difficult-to-treat diseases. We use the capabilities of modern technologies and recent advances in the field of SLC (human transport protein, note) biology to develop new therapies that adhere to SLCs. ” Solgate will focus on the important role of SLCs in neurological diseases, cancer, and will focus on metabolic diseases.
“Implement the vision faster”
We are happy with the new investors and the associated opportunity to “implement the vision much faster.” The startup was founded in 2020 “by a group of distinguished scientists from CeMM” (Center for Molecular Medicine of the Austrian Academy of Sciences) and IST Austria. Subsequently, the young company also received support from Austria Wirtschaftsservice (AWS). “Solgate is the first start-up of a cooperation between CeMM and IST Austria, and it is already the sixth start-up that was created on the basis of CeMM’s inventions and knowledge. We want to thank our investors for the trust they have placed in us and we are confident that the company will be a success ”, said Giulio Superti-Furga, Director of CeMM and co-founder of Solgate. There is no further information on the exact amount of financing.
“Innovative approach”
And how could it be otherwise, they are also satisfied at IST cube: Alexander Schwartz, IST cube partner: “We are looking forward to working with Solgate, whose founders played a key role in the development of the Solute Carriers field and an innovative approach. for the development of new drugs. Solgate is a great example of the potential of the interdisciplinary founding teams of two excellent scientific institutions. We at IST cube are excited about the opportunities Solgate offers. “
IST Cube: 40 million euros of fresh capital for spin-offs of life sciences and technology
